Full-Time
Swine Neonatal Care Technician
eGenesis
51-200 employees
Genetically engineered porcine kidneys for humans
Compensation Overview
$45.8k - $54.1k/yr
Indiana, USA
In Person
On-site in Northwest Indiana; no remote work.
 Lab & Research (1) |
|---|
Get referred to eGenesis
Find people who can refer or advise you
- Exposure to animal handling and basic animal health concerns. Knowledge of equipment disinfection and infection control practices
- An eagerness to learn or further knowledge relating to animal health
- Attention to detail and problem-solving skills
- Excellent communication and teamwork skills
- Proficiency in MS Office
- Schedule flexibility
- Perform daily care of piglets in the eGenesis Neonatal facility
- Take daily weights and temperatures of each piglet
- Clean daily following provided standard operating procedures (SOPs)
- Feed piglets following provided SOPs
- Observe piglets and record clinical observations
- Provide recommended treatments according to veterinary instruction
- Includes giving emergency care and assisting in veterinary procedures such as sedation/anesthesia, venipuncture, and euthanasia
- Record all information in the dedicated databases
- Interpret and report piglet health status
- Express interest in furthering knowledge pertaining to piglet health
- Work with all team members to fully understand each piglet’s medical history
- Communicate piglet clinical signs with supervisor and veterinary staff
- Participate in department, division, and other meetings as requested
- Be responsible to ensure SOP compliance:
- Complete all training on SOPs relative to the position
- Monitor environment for deviations from the SOPs and inform supervisor
- Inform team members and supervisor if any deviations from SOPs are observed to ensure all aspects of the position are being completed correctly
- Promote and adhere to safety in workplace:
- Promote safety awareness
- Correct unsafe acts and conditions and ensure equipment is properly maintained
- Report and investigate all accidents/incidents
- Inspect own area and take remedial action to minimize or eliminate hazards
- Complete required training assignments, forms, and other paperwork
- Ensure compliance with company biosecurity practices to safeguard health of neonatal animals
- Promote and adhere to the eGenesis animal welfare policies:
- Follow all applicable regulatory requirements (USDA, FDA, OLAW) regarding animal welfare and ensure humane care according to the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act
- This position requires that staff work occasional overnight and weekend shifts on a rotating basis shared with other staff, with comp time to accommodate for these schedule changes. As essential personnel, limited on-call or availability for emergency response may occasionally be required.
- AALAS certification (preferred)
- 1+ years of relevant experience in animal research or veterinary care (preferred)
- Knowledge and expertise of veterinary procedures (preferred)
- Knowledge and expertise in animal research (preferred)
eGenesis develops genetically engineered porcine (pig) kidneys and other organs that are compatible with human bodies, aiming to address the organ shortage by enabling transplantations into humans. Its product is created by editing pig genes to reduce rejection and improve compatibility, producing HuCo™ (Human Compatible) organs and cells that can be transplanted by healthcare providers. Unlike many biotech firms that focus on synthetic tissues or other approaches, eGenesis concentrates on xenotransplantation—using animal organs engineered to be accepted by the human immune system—for use in patients awaiting transplants. The company’s goal is to save lives and improve quality of life by expanding the supply of transplantable organs and reducing wait times for patients in need.
Company Size
51-200
Company Stage
Series D
Total Funding
$456M
Headquarters
Cambridge, Massachusetts
Founded
2015
Get referred to eGenesis
Find people who can refer or advise you
Simplify's Take
What believers are saying
- eGenesis raised $191 million Series D financing to advance EGEN-2784 toward first-in-human kidney transplant study.
- FDA granted trial expansion based on positive data from three Expanded Access patients including Tim Andrews.
- eGenesis expanding clinical program to include second successful EGEN-2784 transplant reinforcing platform viability.
What critics are saying
- High-probability retroviral transmission could cause fatal trial patient infection within six to twelve months.
- Acute hyperimmune rejection may lead to trial failure within thirty days affecting EGEN-2784 efficacy.
- First clinical trial patient death could trigger regulatory ban on porcine organ transplants in six to twelve months.
What makes eGenesis unique
- eGenesis uniquely implements all three critical genetic edits for porcine organ safety and efficacy.
- eGenesis achieved world's longest-living recipient of gene-edited pig kidney transplant exceeding seven months.
- eGenesis secured FDA clearance for Phase 1/2/3 clinical trial targeting end-stage kidney disease patients.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Conference Attendance Budget
Professional Development Budget
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -3%2 year growth
↓ -2%eGenesis to participate at BIO International Convention 2026 panel on the future of xenotransplantation. June 18, 2026 CEO & President Mike Curtis joins industry leaders to discuss the clinical progress and potential of xenotransplantation to address the global organ shortage. CAMBRIDGE, Mass. - (BUSINESS WIRE)-eGenesis, a biotechnology company developing human-compatible organs for transplantation, today announced that Michael Curtis, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2026 titled "Xenotransplantation Enters the Clinic: The Next Frontier in Solving Organ Shortage." As xenotransplantation advances from scientific possibility to clinical reality, the panel will examine the latest progress in gene-edited organ transplantation, advances in genome engineering, and the path toward broader clinical adoption. Session Details Xenotransplantation Enters the Clinic: The Next Frontier in Solving Organ Shortage Date: Monday, June 22, 2026 Time: 3:00 p.m. - 4:00 p.m. PT Location: Room 24BC, San Diego Convention Center Panelists: * Jonathan Grinstein, Ph.D., North American Editor, Inside Precision Medicine (Moderator) * Cameron Lillie-Liberto, Kidney Disease Patient Advocate * Jesse Roach, M.D., Senior Vice President, Government Relations, National Kidney Foundation * Xiaoxi (Sofie) Wei, Ph.D., CEO & Co-Founder, X-Therma * David Yang, Partner, Lux Capital "Xenotransplantation is at a pivotal moment as decades of innovation in genome engineering and transplantation science have enabled advancement to clinical studies," said Curtis. "I look forward to joining this distinguished group of experts to discuss the progress being made and the potential for xenotransplantation to expand access to lifesaving organ transplantation for patients around the world." Panelists will discuss the scientific, clinical, regulatory, patient, and investment perspectives shaping the future of xenotransplantation, including how advances in gene editing are addressing immune rejection and viral risk, the design of first-in-human studies, and what it will take to scale xenotransplantation into a viable treatment option for patients with organ failure. More than 800,000 Americans and millions worldwide suffer from end stage kidney disease or ESKD. While organ transplantation remains the gold standard for improving survival and quality of life among those living with kidney failure, due to the shortage of organs, only 27,573 kidney transplants were performed in 2025. For those unable to receive a transplant, dialysis remains the only option. The five-year mortality rate associated with dialysis is approximately 60%, higher than the most common cancers. Genetically engineered porcine-derived kidneys offer a promising solution to this crisis. About eGenesis eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company's proprietary genome engineering platform enables extensive, multiplex gene edits to remove key biological barriers, add protective human transgenes, and inactivate endogenous retroviruses. EGEN-2784, a genetically engineered porcine kidney, is the Company's lead program and is currently being evaluated in a multi-patient Expanded Access study at MGH. The company is also advancing programs focused on acute liver failure and heart failure. eGenesis is headquartered in Cambridge, MA. For more information, visit www.egenesisbio.com. Media Contact
eGenesis to present at 44th Annual J.P. Morgan Healthcare Conference. CAMBRIDGE, Mass. - (BUSINESS WIRE) - eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced that Mike Curtis, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:30 p.m. PT. About eGenesis. eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company's proprietary genome engineering platform enables extensive, multiplex gene edits to remove key biological barriers, add protective human transgenes, and inactivate endogenous retroviruses. EGEN-2784, a genetically engineered porcine kidney, is the Company's lead program and is currently being evaluated in a multi-patient Expanded Access study at MGH. eGenesis is headquartered in Cambridge, MA. For more information, visit www.egenesisbio.com. Kimberly Ha eGenesis [email protected]
Cambridge, MA – eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the close of a $191 million Series D financing. Proceeds will be used to advance the company’s lead product candidate, EGEN-2784, to a first-in-human study for kidney transplant. The funding will also be used to advance … Continued